TABLE 2.
Traita | Prevalence of associated trait [no. (%)]
|
P valuec | |
---|---|---|---|
CGA isolates (n = 15) | Non-CGA isolatesb (n = 22) | ||
F10 papA allele | 9 (60) | 0 (0) | <0.0001 |
F16 papA allele | 6 (40) | 0 (0) | 0.0022 |
papEF | 15 (100) | 3 (14) | <0.0001 |
papG allele II | 6 (40) | 1 (4) | 0.0113 |
afa/dra | 0 (0) | 14 (64) | (<0.0001) |
iha | 14 (93) | 3 (14) | <0.0001 |
sat | 14 (93) | 4 (18) | <0.0001 |
iutA | 14 (93) | 7 (32) | 0.0002 |
kpsM II | 15 (100) | 10 (45) | 0.0004 |
ompT | 15 (100) | 8 (36) | <0.0001 |
Only those traits for which prevalence differences between CGA and non-CGA isolates were statistically significant (Fisher's exact test; P < 0.05) are shown. Trait definitions: papA, P fimbria structural subunit gene; papEF, P fimbria tip pilus gene; papG allele II, P fimbriae adhesion variant II gene; afa/dra, Dr antigen binding adhesin gene; iha, adhesin/siderophore gene; sat, secreted autotransporter toxin gene; iutA, aerobactin receptor gene; kpsM II, group II capsule gene; and ompT, outer membrane protease T gene. Other traits present in CGA but not significantly different in overall prevalence compared with non-CGA isolates,, included papC (P fimbria assembly), fimH (type 1 fimbria adhesin), fyuA (yersiniabactin receptor), and traT (serum resistance-associated gene). Traits absent from CGA isolates but detected among non-CGA isolates included the F12 papA allele, papG allele III, iroN, K1 kpsM II variant, usp, iss, and malX; however, these differences (CGA versus non-CGA) were not statistically significantly by Fisher's exact test.
Non-CGA, TMP-SMZ-resistant control isolates were chosen in a 2:1 ratio to the CGA isolates within each locale, with the exception of San Jose, CA, where only 18 non-CGA, TMP-SMZ resistant isolates were recovered, all of which were used as controls.
The P value in parentheses is for a negative association with CGA.